Willi Kreis

2.9k total citations
87 papers, 2.4k citations indexed

About

Willi Kreis is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Willi Kreis has authored 87 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Molecular Biology, 28 papers in Oncology and 22 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Willi Kreis's work include Prostate Cancer Treatment and Research (21 papers), Biochemical and Molecular Research (15 papers) and Cancer Treatment and Pharmacology (14 papers). Willi Kreis is often cited by papers focused on Prostate Cancer Treatment and Research (21 papers), Biochemical and Molecular Research (15 papers) and Cancer Treatment and Pharmacology (14 papers). Willi Kreis collaborates with scholars based in United States, Japan and Germany. Willi Kreis's co-authors include Daniel R. Budman, Long G. Wang, Catherine Hession, Anthony Calabro, Marian B. Meyers, Maureen M. Goodenow, Dušan Drahovský, James Fetten, Fabian Kalberer and J. Rutschmann and has published in prestigious journals such as Journal of Clinical Oncology, Biochemical and Biophysical Research Communications and Annals of the New York Academy of Sciences.

In The Last Decade

Willi Kreis

86 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Willi Kreis United States 27 1.1k 722 617 271 232 87 2.4k
David G. Priest United States 31 1.5k 1.4× 715 1.0× 277 0.4× 180 0.7× 95 0.4× 102 2.7k
Hitoshi Akedo Japan 31 2.1k 2.0× 793 1.1× 252 0.4× 582 2.1× 108 0.5× 96 3.5k
Enrico Mihich United States 29 1.1k 1.0× 950 1.3× 157 0.3× 242 0.9× 176 0.8× 193 2.9k
Dennis S. France United States 21 1.6k 1.5× 524 0.7× 225 0.4× 437 1.6× 187 0.8× 50 2.6k
Andrew M. Stern United States 32 1.6k 1.5× 644 0.9× 353 0.6× 359 1.3× 70 0.3× 89 3.3k
Lou A. Smets Netherlands 32 1.7k 1.6× 566 0.8× 135 0.2× 526 1.9× 145 0.6× 97 2.9k
Satoshi Toyoshima Japan 32 1.1k 1.1× 412 0.6× 354 0.6× 208 0.8× 123 0.5× 163 2.9k
Frederick S. Philips United States 30 1.1k 1.0× 579 0.8× 170 0.3× 320 1.2× 75 0.3× 71 2.6k
Makoto Asada Japan 21 1.3k 1.2× 563 0.8× 312 0.5× 274 1.0× 58 0.3× 49 2.8k
Masaaki Toda Japan 31 1.2k 1.1× 704 1.0× 522 0.8× 288 1.1× 64 0.3× 194 6.1k

Countries citing papers authored by Willi Kreis

Since Specialization
Citations

This map shows the geographic impact of Willi Kreis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Willi Kreis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Willi Kreis more than expected).

Fields of papers citing papers by Willi Kreis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Willi Kreis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Willi Kreis. The network helps show where Willi Kreis may publish in the future.

Co-authorship network of co-authors of Willi Kreis

This figure shows the co-authorship network connecting the top 25 collaborators of Willi Kreis. A scholar is included among the top collaborators of Willi Kreis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Willi Kreis. Willi Kreis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kreis, Willi, et al.. (2001). Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells. British Journal of Cancer. 85(9). 1403–1411. 25 indexed citations
2.
Budman, Daniel R., Robert D. Johnson, Ronald R. Bowsher, et al.. (2001). Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis. Cancer Chemotherapy and Pharmacology. 47(6). 525–531. 19 indexed citations
3.
Kreis, Willi, Daniel R. Budman, & Anthony Calabro. (2000). A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents. Cancer Chemotherapy and Pharmacology. 47(1). 78–82. 18 indexed citations
4.
Budman, Daniel R., et al.. (2000). Synergism of Cytotoxic Effects of Vinorelbine and Paclitaxel in Vitro. Cancer Investigation. 18(8). 695–701. 35 indexed citations
5.
Kreis, Willi, et al.. (1999). Activation of MAP kinase during apoptosis mediated by vinorelbine in MCF-7 cells. 40. 13–14. 3 indexed citations
6.
7.
Wang, Long G., et al.. (1999). Phosphorylation/Dephosphorylation of Androgen Receptor as a Determinant of Androgen Agonistic or Antagonistic Activity. Biochemical and Biophysical Research Communications. 259(1). 21–28. 43 indexed citations
8.
Wang, Long G., et al.. (1999). The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemotherapy and Pharmacology. 44(5). 355–361. 330 indexed citations
9.
Kreis, Willi, et al.. (1998). Androgen Antagonistic Effect of Estramustine Phosphate (EMP) Metabolites on Wild-Type and Mutated Androgen Receptor. Biochemical Pharmacology. 55(9). 1427–1433. 18 indexed citations
10.
Fetten, James, et al.. (1996). Symptomatic Improvement Associated With Combined Estramustine and Vinblastine Chemotherapy for Metastatic Prostate Cancer. American Journal of Clinical Oncology. 19(6). 581–583. 16 indexed citations
11.
Kreis, Willi, Keith K. H. Chan, Daniel R. Budman, et al.. (1996). Clinical Pharmacokinetics of Amonafide (NSC 308847) in 62 Patients. Cancer Investigation. 14(4). 320–327. 4 indexed citations
12.
Smith, David C., Duncan I. Jodrell, Eleanor G. Zuhowski, et al.. (1993). Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer. Cancer Chemotherapy and Pharmacology. 31(5). 363–368. 5 indexed citations
13.
DeAngelis, Lisa M., et al.. (1992). Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside. Cancer Chemotherapy and Pharmacology. 29(3). 173–177. 30 indexed citations
14.
Budman, Daniel R., Willi Kreis, Philip Schulman, et al.. (1990). Phase I trial of intravenous vinzolidine (LY 104208) given on a biweekly dosing schedule. Investigational New Drugs. 8(3). 269–274. 2 indexed citations
15.
Kreis, Willi, Frederick R. Ahmann, Martin Lesser, et al.. (1990). Predictive initial parameters for response of stage D prostate cancer to treatment with the luteinizing hormone-releasing hormone agonist goserelin.. Journal of Clinical Oncology. 8(5). 870–874. 19 indexed citations
16.
Meyers, Marian B. & Willi Kreis. (1978). Comparison of enzymatic activities of two deoxycytidine kinases purified from cells sensitive (P815) or resistant (P815/ara-C) to 1-beta-D-arabinofuranosylcytosine.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 38(4). 1105–12. 26 indexed citations
17.
Kreis, Willi & Maureen M. Goodenow. (1978). Methionine requirement and replacement by homocysteine in tissue cultures of selected rodent and human malignant and normal cells.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 38(8). 2259–62. 69 indexed citations
18.
Meyers, Marian B. & Willi Kreis. (1978). Structural comparison of deoxycytidine kinases purified from cells sensitive (P815) or resistant (P815/ara-C) to 1-beta-D-arabinofuranosylcytosine.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 38(4). 1099–104. 10 indexed citations
19.
Kreis, Willi, Catherine Hession, Andrea Soricelli, & Kathleen M. Scully. (1977). Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 61(7). 1355–64. 11 indexed citations
20.
Kreis, Willi, et al.. (1977). Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man.. PubMed. 61(7). 1347–53. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David G. Priest Breakdown of academic impact, for papers by Hitoshi Akedo Breakdown of academic impact, for papers by Enrico Mihich Breakdown of academic impact, for papers by Dennis S. France Breakdown of academic impact, for papers by Andrew M. Stern Breakdown of academic impact, for papers by Lou A. Smets Breakdown of academic impact, for papers by Satoshi Toyoshima Breakdown of academic impact, for papers by Frederick S. Philips Breakdown of academic impact, for papers by Makoto Asada Breakdown of academic impact, for papers by Masaaki Toda
Rankless by CCL
2026